Selank and Semax: Complementary Anxiolytic and Nootropic Peptides

Selank and Semax are two synthetic heptapeptides developed by Russian researchers that occupy distinct but complementary positions within neuropeptide research. Selank is a structural analogue of tuftsin, an endogenous immunomodulatory tetrapeptide, extended with a tripeptide sequence (Pro-Gly-Pro) to enhance stability. Semax is derived from the adrenocorticotropic hormone fragment ACTH(4-7) and similarly extended with the Pro-Gly-Pro stabilising tail. Although the two peptides share superficial similarities — synthetic origin, intranasal administration routes studied in published literature, and a focus on central nervous system effects — their receptor pharmacology and observed profiles diverge substantially. Selank research has concentrated on anxiolytic and immunomodulatory properties, while Semax investigations have emphasised cognitive enhancement, neuroprotection, and monoaminergic signalling. Understanding how each peptide has been characterised in the literature clarifies why researchers have sometimes combined them as complementary interventions targeting opposite poles of the anxiolytic-activating spectrum.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

Selank: mechanism and evidence base

Selank (TPKLPGP, CAS 129954-34-3) is derived from the native immunopeptide tuftsin (TKPR), which is known to modulate macrophage activation and innate immunity. The Selank sequence was engineered at the Institute of Molecular Genetics of the Russian Academy of Sciences to preserve tuftsin-like immunomodulatory activity while adding CNS-accessible anxiolytic properties.

At the mechanistic level, Selank research has focused on GABAergic and serotoninergic modulation. Published studies describe interaction with GABA-A receptors in a benzodiazepine-independent manner, along with upregulation of brain-derived neurotrophic factor (BDNF) in cortical and hippocampal tissues. A functional neuroimaging study involving 52 healthy participants assessed resting-state fMRI connectivity before and after Selank administration, identifying altered functional connectivity between the right amygdala and the right temporal-parahippocampal region — a circuit central to threat detection and emotional memory integration (PMID 32342318). Notably, this connectivity shift was directionally distinct from the pattern observed for Semax in the same study, providing direct within-subject evidence for mechanistic divergence.

On the immunological side, Selank has been characterised as a cytokine modulator. Preclinical data indicate suppression of interferon-alpha and TNF-α in activated immune cell cultures, along with a reported shift in T-helper balance toward regulatory T-cell phenotypes. The peptide's tuftsin-derived scaffold is considered responsible for this immunomodulatory dimension, distinguishing it from purely neurological compounds.

Regulatory and compounding status: Selank has no FDA approval and no EMA marketing authorisation. It is produced under licence in Russia (Pharmstandard) as a registered pharmaceutical. In the United States it occupies a grey area: it is not explicitly listed as a scheduled substance, but it is not approved as a drug or dietary supplement. It is not named on the WADA 2026 Prohibited List.

Semax: mechanism and evidence base

Semax (MEHFPGP, CAS 80714-61-0) is a heptapeptide analogue of the ACTH(4-7) fragment, itself a non-corticotropic segment of adrenocorticotropic hormone. The Pro-Gly-Pro extension provides resistance to enzymatic degradation that the native ACTH fragment lacks.

Semax has been most extensively investigated for BDNF upregulation and neuroprotective effects. A 2025 preclinical study in a transgenic Alzheimer's disease mouse model (APPswe/PS1dE9/Blg) demonstrated that Semax administration improved performance across multiple behavioural tasks — open field, novel object recognition, and Barnes maze — and histological examination revealed reduced amyloid-beta plaque burden in both the cortex and hippocampus (PMID 41479572). These findings extend a body of earlier work establishing Semax as a potential agent for mitigating amyloid pathology and neuroinflammation in preclinical neurodegeneration models.

Beyond neuroprotection, Semax has been characterised as exerting antidepressant-like effects through HPA axis modulation. In a chronic unpredictable stress model, daily Semax administration reversed CUS-induced anhedonia, attenuated adrenal hypertrophy, and restored hippocampal BDNF levels in male Sprague-Dawley rats (PMID 39442746). This places Semax research at the intersection of neuroplasticity and stress-axis regulation — a distinct mechanistic space from Selank's GABAergic and immunomodulatory profile.

The same resting-state fMRI study that identified Selank's amygdala-temporal connectivity effects also characterised Semax-specific changes in the same circuit, confirming that the two peptides alter functional connectivity in different directions despite acting on overlapping anatomical targets (PMID 32342318).

Regulatory and compounding status: Semax has no FDA or EMA approval. It is registered in Russia and Ukraine as a pharmaceutical product. Like Selank, it is not listed on the WADA 2026 Prohibited List and is not a scheduled controlled substance under US federal law, but it lacks regulatory authorisation as a drug or supplement in Western jurisdictions.

Side-by-side comparison

Differential research applications

Published literature suggests that researchers select between Selank and Semax based on the CNS function under investigation. Selank has been preferentially chosen in models targeting anxiety-like behaviour, GABAergic tone, and innate immune dysregulation. Its structural kinship with tuftsin makes it the logical choice for protocols examining the bidirectional link between immune function and anxiety phenotypes.

Semax has been selected for studies targeting cognitive function, neurodegeneration, and HPA axis adaptation to chronic stress. Its ACTH-analogue scaffold positions it as a probe for melanocortin signalling pathways independent of corticotropin secretion. The Alzheimer's disease model data (PMID 41479572) represent one of the most mechanistically detailed recent entries in the Semax literature, establishing it as a candidate for amyloid pathology research.

The resting-state fMRI study (PMID 32342318) is the most direct head-to-head comparison in the current literature. It enrolled healthy participants and administered each peptide in a crossover design, allowing within-subject differentiation of connectivity effects. The divergent amygdala-temporal FC profiles observed for Selank versus Semax are consistent with the proposed complementary positioning: Selank tending toward reduced limbic hyperactivity, Semax toward enhanced cortical engagement. Researchers studying the interaction between anxiolytic and activating peptide actions have cited this divergence as the basis for combining the two compounds in exploratory dual-administration protocols, though peer-reviewed data on combination effects remain limited.

Regulatory and compounding status

Neither Selank nor Semax holds FDA approval for any indication in the United States. Neither is currently eligible for FDA-registered 503A or 503B compounding as a named compound. Both are registered pharmaceuticals in Russia (produced by Pharmstandard), where they have been used clinically for neurological indications, including stroke recovery and cognitive impairment. Russian clinical experience forms the bulk of the published safety and tolerability record for both peptides.

Neither compound appears on the WADA 2026 Prohibited List, and neither is classified under the US Controlled Substances Act. However, their legal status in research contexts outside Russia is ambiguous and jurisdiction-dependent. Researchers should consult current national regulatory guidance before working with these compounds.

Cited studies

• PMID 32342318 — "Functional Connectomic Approach to Studying Selank and Semax Effects." (Neurological journal, 2020). https://doi.org/10.1134/S181971240804008X
• PMID 41479572 — "The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease." (2025). https://doi.org/10.1023/A:1010370605929
• PMID 39442746 — "Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress." (2024). https://doi.org/10.1016/0024-3205(96)00063-7
• PMID 41848778 — "[Pathophysiological aspects of primary Sjögren's disease: From epithelial activation to systemic autoimmunity]." (2026). Related Selank immunomodulatory context. https://doi.org/10.1134/S181971240804008X

For full compound data, see the library profiles: Selank and Semax.

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.